Unnamed: 0,title,date,stock,sentiment
430473.0,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,2020-06-01 16:00:00-04:00,EPZM,neutral
430474.0,Epizyme To Present Data From Tazemetostat At ASCO May 29,2020-05-13 17:40:00-04:00,EPZM,neutral
430475.0,"Oppenheimer Maintains Perform on Epizyme, Raises Price Target to $17",2020-05-05 08:51:00-04:00,EPZM,neutral
430476.0,Epizyme: Q1 Earnings Insights,2020-05-04 07:04:00-04:00,EPZM,neutral
430477.0,"Epizyme Q1 EPS $(0.51) Beats $(0.74) Estimate, Sales $1.354M Miss $3.680M Estimate",2020-05-04 06:33:00-04:00,EPZM,negative
430478.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,EPZM,neutral
430479.0,Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.,2020-04-08 09:34:00-04:00,EPZM,positive
430480.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 09:42:00-04:00,EPZM,positive
430481.0,"Oppenheimer Downgrades Epizyme to Perform, Lowers Price Target to $16",2020-04-01 08:48:00-04:00,EPZM,negative
430482.0,Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.,2020-03-11 07:15:00-04:00,EPZM,neutral
430483.0,"Benzinga's Top Upgrades, Downgrades For March 4, 2020",2020-03-04 10:08:00-05:00,EPZM,positive
430484.0,Epizyme shares are trading higher after Barclays initiated coverage on the stock with an Overweight rating and a price target of $33 per share.,2020-03-04 10:01:00-05:00,EPZM,positive
430485.0,"Barclays Initiates Coverage On Epizyme with Overweight Rating, Announces $33 Price Target",2020-03-04 05:38:00-05:00,EPZM,negative
430486.0,"Epizyme shares are trading higher on a rebound after the stock dipped following the release of Q4 earnings on Monday. UPDATE: Shares have since reversed, now lower.",2020-02-25 10:17:00-05:00,EPZM,positive
430487.0,77 Biggest Movers From Yesterday,2020-02-25 04:30:00-05:00,EPZM,neutral
430488.0,55 Stocks Moving In Monday's Mid-Day Session,2020-02-24 13:10:00-05:00,EPZM,neutral
430489.0,"Epizyme shares are trading lower following Q4 results. NOTE: Weakness may also be market related, as global equities are lower for the session amid coronavirus fears.",2020-02-24 09:08:00-05:00,EPZM,negative
430490.0,"Epizyme Q4 EPS $(0.59) Misses $(0.5) Estimate, Sales $4.294M Beat $3.08M Estimate",2020-02-24 06:31:00-05:00,EPZM,negative
430491.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,EPZM,neutral
430492.0,76 Biggest Movers From Friday,2020-02-18 05:13:00-05:00,EPZM,neutral
430493.0,Epizyme shares are trading higher after the company announced FDA accepted for filing the company's New Drug Application for the accelerated approval of TAZVERIK.,2020-02-14 10:54:00-05:00,EPZM,positive
430494.0,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering",2020-02-14 08:23:00-05:00,EPZM,negative
430495.0,Epizyme Reports FDA Acceptance Of New Drug Application For Filing With Priority Review For TAZVERIK For Treatment Of Follicular Lymphoma,2020-02-14 06:34:00-05:00,EPZM,positive
430496.0,Epizyme shares are trading higher after hearing the company's Tazemetostat has been added to the National Comprehensive Cancer Network Guidelines as a category 2A recommendation for the treatment of soft-tissue sarcoma.,2020-02-10 13:27:00-05:00,EPZM,negative
430497.0,Epizyme Shares Spike To Session High As Hearing Co.'s Tazemetostat Has Been Added To National Comprehensive Cancer Network Guideliness As Category 2A Recommendation For Treatment Of Soft-Tissue Sarcoma,2020-02-10 12:03:00-05:00,EPZM,negative
430498.0,"Epizyme shares are trading lower in sympathy with the overall market as the Wuhan coronavirus continues to spread throughout the country, prompting travel bans in multiple Chinese cities. Reports say the death toll rose to 80 as of Sunday.",2020-01-27 09:07:00-05:00,EPZM,negative
430499.0,70 Biggest Movers From Friday,2020-01-27 04:02:00-05:00,EPZM,neutral
430500.0,"The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes",2020-01-26 10:23:00-05:00,EPZM,neutral
430501.0,Epizyme shares are trading lower despite the company receiving accelerated FDA approval for TAZVERIK. A Wedbush analysts noted a 'relatively low initial price point' for the drug.,2020-01-24 14:21:00-05:00,EPZM,positive
430502.0,44 Stocks Moving In Friday's Mid-Day Session,2020-01-24 12:08:00-05:00,EPZM,neutral
430503.0,Epizyme Shares Down 9% Despite Accelerated FDA Approval For Its Epithelioid Sarcoma Treatment; Wedbush Analyst David Nierengarten Attributes Move To Potential 'Sell On The News' Response As Well Potential Lower-Than-Expected Pricing Of The Drug,2020-01-24 10:23:00-05:00,EPZM,positive
430504.0,"Morgan Stanley Maintains Overweight on Epizyme, Raises Price Target to $28",2020-01-24 09:28:00-05:00,EPZM,negative
430505.0,Epizyme shares are trading lower despite the company receiving accelerated FDA approval for TAZVERIK.,2020-01-24 09:23:00-05:00,EPZM,positive
430506.0,"Wedbush Maintains Outperform on Epizyme, Raises Price Target to $30",2020-01-24 08:23:00-05:00,EPZM,neutral
430507.0,"The Daily Biotech Pulse: FDA Nod For Epizyme, Sonoma Explores Options For Dermatology Business, Roche's Cancer Drug Flunks Study",2020-01-24 07:43:00-05:00,EPZM,negative
430508.0,Epizyme's Tazemetostat Drug For Epithelioid Sarcoma Gets Accelerated FDA Approval,2020-01-24 05:52:00-05:00,EPZM,positive
430509.0,"Benzinga Pro's Top 5 Stocks To Watch For Thurs., Jan. 23, 2020: CODX, LUV, INTC, PAYC, EPZM",2020-01-23 09:04:00-05:00,EPZM,positive
430510.0,Epizyme shares are trading higher after Citigroup maintained its Buy rating on the stock and raised its price target from $25 to $35 per share.,2020-01-23 09:00:00-05:00,EPZM,positive
430511.0,"Citigroup Maintains Buy on Epizyme, Raises Price Target to $35",2020-01-23 08:01:00-05:00,EPZM,neutral
430512.0,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",2020-01-23 07:24:00-05:00,EPZM,positive
430513.0,Watch Epizyme Shares Thurs. Amid PDUFA Date For Tazemetostat For Epithelioid Sarcoma,2020-01-23 07:17:00-05:00,EPZM,positive
430514.0,36 Stocks Moving in Thursday's Pre-Market Session,2020-01-23 07:16:00-05:00,EPZM,neutral
430515.0,"The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings",2020-01-22 08:25:00-05:00,EPZM,neutral
430516.0,Stocks That Hit 52-Week Highs On Tuesday,2020-01-21 10:11:00-05:00,EPZM,neutral
430517.0,"The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings",2020-01-20 14:04:00-05:00,EPZM,neutral
430518.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,EPZM,neutral
430519.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,EPZM,negative
430520.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,EPZM,neutral
430521.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,EPZM,neutral
430522.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-15 13:14:00-05:00,EPZM,neutral
430523.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,EPZM,negative
430524.0,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results",2020-01-08 08:12:00-05:00,EPZM,positive
430525.0,Epizyme Exercises its Option to Sell $50M of Stock to Royalty Pharma,2020-01-06 06:40:00-05:00,EPZM,neutral
430526.0,"The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger",2020-01-03 07:55:00-05:00,EPZM,negative
430527.0,Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates,2020-01-01 18:00:00-05:00,EPZM,neutral
430528.0,36 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-19 08:28:00-05:00,EPZM,neutral
430529.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,EPZM,negative
430530.0,64 Biggest Movers From Yesterday,2019-12-19 05:03:00-05:00,EPZM,neutral
430531.0,Epizyme Reports Submission Of New Drug Application For Tazemetostat For Treatment Of Patients With Follicular Lymphoma,2019-12-18 17:27:00-05:00,EPZM,neutral
430532.0,Epizyme shares are trading higher after the FDA advisory committee voted unanimously in favor of Tazemetostat for the treatment of patients with epithelioid sarcoma.,2019-12-18 14:31:00-05:00,EPZM,positive
430533.0,Epizyme Shares Resume Trade,2019-12-18 14:30:00-05:00,EPZM,positive
430534.0,Epizyme Shares To Resume Trade At 2:30 p.m. EDT,2019-12-18 14:12:00-05:00,EPZM,positive
430535.0,Epizyme Announces FDA Advisory Committee Votes Unanimously in Favor of Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma,2019-12-18 14:03:00-05:00,EPZM,positive
430536.0,Hearing FDA AdCom Panel Votes 11-0 Benefits Of Epizyme's Tazemetostat Outweight Risks,2019-12-18 11:45:00-05:00,EPZM,positive
430537.0,FDA Votes Unanimously In Favor Of Epizyme's Tazemetostat,2019-12-18 11:10:00-05:00,EPZM,positive
430538.0,"Benzinga Pro's Top 5 Stocks To Watch For Wed., Dec. 18, 2019: UPS, MU, EPZM, SLDB, XXII",2019-12-18 08:46:00-05:00,EPZM,positive
430539.0,"The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data",2019-12-18 07:23:00-05:00,EPZM,positive
430540.0,UPDATE: Epizyme Shares Halted Ahead Of FDA Adcom,2019-12-18 06:57:00-05:00,EPZM,positive
430541.0,"Epizyme Shares Halted, News Pending",2019-12-18 06:55:00-05:00,EPZM,positive
430542.0,"The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week",2019-12-15 15:49:00-05:00,EPZM,neutral
430543.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,EPZM,positive
430544.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-09 08:26:00-05:00,EPZM,neutral
430545.0,74 Biggest Movers From Friday,2019-12-09 05:22:00-05:00,EPZM,neutral
430546.0,Epizyme Presents Updated Phase 2 Data Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma at ASH 2019,2019-12-07 13:45:00-05:00,EPZM,positive
430547.0,55 Stocks Moving In Friday's Mid-Day Session,2019-12-06 12:02:00-05:00,EPZM,neutral
430548.0,Stocks That Hit 52-Week Highs On Friday,2019-12-06 10:33:00-05:00,EPZM,neutral
430549.0,Epizyme shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised the price action from $12 to $22 per share.,2019-12-06 10:31:00-05:00,EPZM,positive
430550.0,"Benzinga's Top Upgrades, Downgrades For December 6, 2019",2019-12-06 10:24:00-05:00,EPZM,positive
430551.0,10 Biggest Price Target Changes For Friday,2019-12-06 08:11:00-05:00,EPZM,neutral
430552.0,"The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",2019-12-06 07:39:00-05:00,EPZM,positive
430553.0,A Peek Into The Markets: US Stock Futures Up; Jobs Report In Focus,2019-12-06 06:38:00-05:00,EPZM,neutral
430554.0,"Morgan Stanley Upgrades Epizyme to Overweight, Raises Price Target to $22",2019-12-06 06:22:00-05:00,EPZM,negative
430555.0,"The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug",2019-11-26 08:06:00-05:00,EPZM,positive
430556.0,"The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate",2019-11-22 08:18:00-05:00,EPZM,positive
430557.0,Stocks That Hit 52-Week Highs On Thursday,2019-11-21 10:39:00-05:00,EPZM,neutral
430558.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,EPZM,positive
430559.0,RPI Finance Trust Reports 9.1% Share Stake In Epizyme Inc As Of November 6; RPI Finance Says It Acquired Epizyme Securities For Investment Purposes,2019-11-18 12:49:00-05:00,EPZM,positive
430560.0,61 Biggest Movers From Yesterday,2019-11-06 04:19:00-05:00,EPZM,neutral
430561.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-11-05 12:10:00-05:00,EPZM,neutral
430562.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,EPZM,negative
430563.0,Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement,2019-11-04 07:38:00-05:00,EPZM,positive
430564.0,"Epizyme Announces 'Positive' Pre-NDA Meeting For Tazemetostat For Follicular Lymphoma, Pipeline Updates And Third Quarter 2019 Results",2019-10-30 06:43:00-04:00,EPZM,neutral
430565.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,EPZM,neutral
430566.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,EPZM,negative
430567.0,Epizyme Sees Its Cash Runway Extending Into Q1'21,2019-08-09 06:31:00-04:00,EPZM,neutral
430568.0,"Epizyme Q2 EPS $(0.53), Inline, Sales $5.9M Beat $1.75M Estimate",2019-08-09 06:31:00-04:00,EPZM,neutral
430569.0,Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma,2019-07-25 06:34:00-04:00,EPZM,positive
430570.0,51 Biggest Movers From Yesterday,2019-06-26 05:53:00-04:00,EPZM,neutral
430571.0,68 Biggest Movers From Friday,2019-06-24 04:25:00-04:00,EPZM,neutral
430572.0,Epizyme Highlights Presentation Of Updated Data From Phase 2 Trial Of Tazemetostat In Patients With Relapsed Or Refractory Follicular Lymphoma; Data Showed  'Durable and Clinically Meaningful Responses',2019-06-21 07:46:00-04:00,EPZM,positive
430573.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,EPZM,positive
430574.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs",2019-06-15 12:38:00-04:00,EPZM,neutral
430575.0,50 Biggest Movers From Yesterday,2019-06-13 05:44:00-04:00,EPZM,neutral
430576.0,35 Stocks Moving In Wednesday's Mid-Day Session,2019-06-12 12:54:00-04:00,EPZM,neutral
430577.0,Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat For Epithelioid Sarcoma at #ASCO19; New Clinical Data Presented Today Included In Recently Submitted NDA to FDA,2019-06-03 06:31:00-04:00,EPZM,neutral
430578.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,EPZM,neutral
430579.0,Epizyme Highlights Submission Of New Drug Application To FDA For Tazemetostat For Treatment Of Patients With Epithelioid Sarcoma,2019-05-30 06:30:00-04:00,EPZM,neutral
430580.0,A Peek Into The Markets: US Stock Futures Tumble; Dow Futures Down Over 500 Points,2019-05-06 07:07:00-04:00,EPZM,neutral
430581.0,Epizyme Says Has Cash Runway To Extend Into At Least Q1'21,2019-05-06 06:32:00-04:00,EPZM,positive
430582.0,"Epizyme Q1 EPS $(0.39) Beats $(0.46) Estimate, Sales $7.9M Beat $2.16M Estimate",2019-05-06 06:31:00-04:00,EPZM,neutral
430583.0,Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.,2019-04-18 10:42:00-04:00,EPZM,negative
430584.0,Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.,2019-04-17 10:38:00-04:00,EPZM,positive
430585.0,26 Stocks Moving In Thursday's Pre-Market Session,2019-03-07 08:01:00-05:00,EPZM,neutral
430586.0,"Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO",2019-03-07 07:48:00-05:00,EPZM,negative
430587.0,Epizyme Prices 10M Share Common Stock Offering @$11.50/Share,2019-03-07 03:42:00-05:00,EPZM,positive
430588.0,"Epizyme Reports Offering Of Common Stock, Series A Preferred Shares, No Size Disclosed",2019-03-06 16:03:00-05:00,EPZM,neutral
430589.0,Epizyme 8-K Shows Partial Clinical Hold On New Patient Enrollment For Studies Of Tazemetostat In France Has Been Lifted,2019-03-01 06:31:00-05:00,EPZM,neutral
430590.0,72 Biggest Movers From Yesterday,2019-02-27 04:55:00-05:00,EPZM,neutral
430591.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-02-26 12:18:00-05:00,EPZM,neutral
430592.0,Epizyme shares are trading higher after the company beat Q4 EPS estimates.,2019-02-26 11:35:00-05:00,EPZM,positive
430593.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,EPZM,positive
430594.0,Epizyme Q4 EPS $(0.29) Beats $(0.48) Estimate,2019-02-26 06:33:00-05:00,EPZM,neutral
430595.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,EPZM,neutral
430596.0,Shares of several cancer therapeutics companies are trading higher after Loxo Oncology received an acquisition offer from Eli Lilly.,2019-01-07 10:57:00-05:00,EPZM,negative
430597.0,Epizyme shares are trading higher after the Leerink Swann Upgraded the company's stock from Market Perform to Outperform.,2019-01-07 10:27:00-05:00,EPZM,positive
430598.0,Leerink Swann Upgrades Epizyme to Outperform,2019-01-07 09:13:00-05:00,EPZM,neutral
430599.0,21 Stocks Moving In Monday's Pre-Market Session,2019-01-07 08:09:00-05:00,EPZM,neutral
430600.0,58 Biggest Movers From Friday,2019-01-07 04:17:00-05:00,EPZM,neutral
430601.0,"Epizyme Shares Spike To Session High Over $7.50 Level Over Last Few Mins., Now Over $8 Level, Up 34.3%",2019-01-04 15:45:00-05:00,EPZM,positive
430602.0,41 Stocks Moving In Friday's Mid-Day Session,2019-01-04 12:17:00-05:00,EPZM,neutral
430603.0,"Epizyme shares are trading higher after the company announced a registration path for Tazemetostate, provided pipeline updates, and stated FY19 guidance.",2019-01-04 09:29:00-05:00,EPZM,positive
430604.0,UPDATE: Epizyme Sees Capital Runway Into Q2'20,2019-01-04 06:34:00-05:00,EPZM,neutral
430605.0,"Epizyme Outlines Registration Path For Tazemetostat; Offers Pipeline, FY19 Guidance",2019-01-04 06:33:00-05:00,EPZM,neutral
430606.0,58 Biggest Movers From Yesterday,2019-01-04 05:35:00-05:00,EPZM,neutral
430607.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,EPZM,neutral
430608.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,EPZM,negative
430609.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,EPZM,positive
430610.0,Epizyme Earns $8M Milestone Payment From GlaxoSmithKline For Initiation Of Clinical Development For PRMT1 Inhibitor,2018-12-18 06:34:00-05:00,EPZM,negative
430611.0,"Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018",2018-12-17 11:48:00-05:00,EPZM,negative
430612.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,EPZM,negative
430613.0,"The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch",2018-12-14 07:47:00-05:00,EPZM,neutral
430614.0,"The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen",2018-12-13 07:56:00-05:00,EPZM,positive
430615.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 11, 2018",2018-12-12 11:47:00-05:00,EPZM,negative
430616.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,EPZM,negative
430617.0,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",2018-12-07 08:04:00-05:00,EPZM,neutral
430618.0,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering",2018-12-06 07:56:00-05:00,EPZM,negative
430619.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018",2018-11-23 09:09:00-05:00,EPZM,negative
430620.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018",2018-11-21 08:50:00-05:00,EPZM,negative
430621.0,"The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results",2018-11-15 08:10:00-05:00,EPZM,positive
430622.0,"Epizyme To Host Conference Call Thurs., Nov. 15, 2018 At 8:30 a.m. EST To Discuss Corporate Updates",2018-11-15 06:37:00-05:00,EPZM,neutral
430623.0,"UPDATE: Epizyme Will Be Eligible To Receive Upfront Payment Of $15M Plus Added $5M in Research Funding In 2019; Is Eligible To Receive $280M+ In Added Payments For R&D, Regulatory, Commercial Milestones",2018-11-15 06:36:00-05:00,EPZM,neutral
430624.0,Epizyme Reports Global Collaboration With Boehringer Ingelheim To Develop Novel Epigenetic Oncology Therapies,2018-11-15 06:33:00-05:00,EPZM,positive
430625.0,Epizyme Q3 EPS $(0.54) Beats $(0.61) Estimate,2018-11-02 06:33:00-04:00,EPZM,neutral
430626.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,EPZM,negative
430627.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,EPZM,negative
430628.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,EPZM,negative
430629.0,"The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",2018-10-23 08:35:00-04:00,EPZM,positive
430630.0,"Benzinga's Week Ahead: Can Tech Earnings Restore The Rally? Amazon, Google To Report",2018-10-22 12:49:00-04:00,EPZM,positive
430631.0,"REMINDER: ESMO 2018 Event Continues Today, Clinical Updates Presented Today Include: CytomX Therapeutics, Mirati Therapeutics, Merck, NuCana, Protagonist Therapeutics, SELLAS Life Sciences, Epizyme, Kura Oncology, Intra-Cellular Therapies, and AVEO Pharma",2018-10-22 05:56:00-04:00,EPZM,neutral
430632.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,EPZM,neutral
430633.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",2018-10-14 13:21:00-04:00,EPZM,neutral
430634.0,55 Biggest Movers From Yesterday,2018-10-04 05:29:00-04:00,EPZM,neutral
430635.0,43 Stocks Moving In Wednesday's Mid-Day Session,2018-10-03 13:09:00-04:00,EPZM,neutral
430636.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-10-03 08:10:00-04:00,EPZM,neutral
430637.0,"The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares",2018-10-03 07:54:00-04:00,EPZM,positive
430638.0,"8 Stocks To Watch For October 3, 2018",2018-10-03 04:46:00-04:00,EPZM,neutral
430639.0,Epizyme Prices 8.3M Share Public Offering of Common Stock @$9/Share,2018-10-03 03:53:00-04:00,EPZM,positive
430640.0,7 Stocks Moving In Tuesday's After-Hours Session,2018-10-02 16:39:00-04:00,EPZM,neutral
430641.0,"Epizyme Reports Offering Of Common Stock, No Size Disclosed",2018-10-02 16:01:00-04:00,EPZM,negative
430642.0,"Leerink Swann Initiates Coverage On Epizyme with Market Perform Rating, Announces $11 Price Target",2018-09-25 08:52:00-04:00,EPZM,neutral
430643.0,42 Stocks Moving In Monday's Mid-Day Session,2018-09-24 12:39:00-04:00,EPZM,neutral
430644.0,24 Stocks Moving In Monday's Pre-Market Session,2018-09-24 08:27:00-04:00,EPZM,neutral
430645.0,Epizyme Announces FDA Lifts Partial Clinical Hold on Tazemetostat Clinical Program,2018-09-24 06:31:00-04:00,EPZM,neutral
430646.0,"Morgan Stanley Reinstates Equal-Weight on Epizyme, Announces $12 Price Target",2018-09-07 07:48:00-04:00,EPZM,neutral
430647.0,Court Filing Shows A US Judge Has Blocked State Of Texas's Fetal Tissue Burial Law,2018-09-05 15:08:00-04:00,EPZM,negative
430648.0,"Stocks Which Set New 52-Week Low Yesterday, August 2nd",2018-08-03 11:22:00-04:00,EPZM,negative
430649.0,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",2018-08-03 07:52:00-04:00,EPZM,neutral
430650.0,75 Biggest Movers From Yesterday,2018-08-03 06:10:00-04:00,EPZM,neutral
430651.0,65 Stocks Moving In Thursday's Mid-Day Session,2018-08-02 12:26:00-04:00,EPZM,neutral
430652.0,Mid-Day Market Update: Cross Country Healthcare Drops After Downbeat Q2 Results; InnSuites Hospitality Trust Shares Climb,2018-08-02 12:00:00-04:00,EPZM,positive
430653.0,Epizyme shares are trading 15% lower after the company announced mixed quarterly earnings. The company also announced it has terminated development of tazemetostat for large B-cell lymphoma due to lack of efficacy.,2018-08-02 10:02:00-04:00,EPZM,negative
430654.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,EPZM,positive
430655.0,Epizyme Q2 EPS $(0.42) Beats $(0.51) Estimate,2018-08-02 07:03:00-04:00,EPZM,neutral
430656.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,EPZM,neutral
430657.0,45 Biggest Movers From Tuesday,2018-07-05 04:40:00-04:00,EPZM,neutral
430658.0,34 Stocks Moving In Tuesday's Mid-Day Session,2018-07-03 12:30:00-04:00,EPZM,neutral
430659.0,Mid-Day Market Update: U.S. Stocks Turn Negative; Anavex Life Sciences Shares Spike Higher,2018-07-03 12:15:00-04:00,EPZM,negative
430660.0,Mid-Morning Market Update: Markets Open Higher; Acuity Brands Beats Q3 Expectations,2018-07-03 10:14:00-04:00,EPZM,neutral
430661.0,6 Biggest Price Target Changes For Tuesday,2018-07-03 09:37:00-04:00,EPZM,neutral
430662.0,"Benzinga's Top Upgrades, Downgrades For July 3, 2018",2018-07-03 09:00:00-04:00,EPZM,positive
430663.0,Leerink Swann Downgrades Epizyme to Market Perform,2018-07-03 06:52:00-04:00,EPZM,neutral
430664.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,EPZM,neutral
430665.0,Epizyme Reports Positive Updated Interim Data From Phase 2 Study Of Tazemetostat In Patients With Relapsed Or Refractory Follicular Lymphoma At Congress Of The European Hematology Association (EHA),2018-06-15 08:10:00-04:00,EPZM,positive
430666.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,EPZM,negative
430667.0,Epizyme Presents Encouraging Phase 2 Data of Tazemetostat for Malignant Mesothelioma at #ASCO2018,2018-06-03 19:12:00-04:00,EPZM,positive
430668.0,5 Biggest Price Target Changes For Friday,2018-05-18 09:58:00-04:00,EPZM,neutral
430669.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,EPZM,neutral
430670.0,"Epizyme Says Existing Cash, Cash Equivalents, Marketable Securities Will Be Sufficient To Fund Planned Operations Into Q3'19",2018-05-08 07:37:00-04:00,EPZM,positive
430671.0,Epizyme Q1 EPS $(0.49) Beats $(0.54) Estimate,2018-05-08 07:35:00-04:00,EPZM,neutral
430672.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,EPZM,neutral
430673.0,38 Biggest Movers From Yesterday,2018-04-25 04:12:00-04:00,EPZM,neutral
430674.0,Mid-Afternoon Market Update: Dow Falls Over 500 Points; Santander Consumer USA Shares Gain On Earnings Beat,2018-04-24 14:31:00-04:00,EPZM,positive
430675.0,"'We Expect A Quick Resolution': Despite Partial Clinical Hold On Epizyme's Drug Candidate, Wedbush Stays Bullish",2018-04-24 13:14:00-04:00,EPZM,neutral
430676.0,32 Stocks Moving In Tuesday's Mid-Day Session,2018-04-24 12:26:00-04:00,EPZM,neutral
430677.0,Mid-Day Market Update: Sanmina Surges Following Q2 Beat; Valeritas Shares Slide,2018-04-24 12:00:00-04:00,EPZM,positive
430678.0,Mid-Morning Market Update: Markets Mostly Flat; Coca-Cola Beats Q1 Views,2018-04-24 10:24:00-04:00,EPZM,neutral
430679.0,Epizyme Shares Drop After Partial Clinical Hold Placed On Lead Cancer Drug,2018-04-24 09:24:00-04:00,EPZM,negative
430680.0,Epizyme Shares Down 17.3% After Hours Following Announcement Of Temporary Clinical Hold On Patient Enrollment For Tazemetostat; Co. Must Confirm Alignment With FDA To Resume Enrollment,2018-04-23 17:29:00-04:00,EPZM,positive
430681.0,Epizyme Shares To Resume Trade At 5:15 p.m. EDT,2018-04-23 16:54:00-04:00,EPZM,positive
430682.0,"Epizyme Announces Temporary Clinical Hold On Patient Enrollment For Tazemetostat, Will Need To Confirm Alignment With FDA To Resume Enrollment",2018-04-23 16:46:00-04:00,EPZM,neutral
430683.0,Epizyme Shares Halted News Pending,2018-04-23 16:42:00-04:00,EPZM,positive
430684.0,"Epizyme Files For Potential Mixed Shelf Offering, Size Not Disclosed",2018-04-05 16:46:00-04:00,EPZM,neutral
430685.0,35 Stocks Moving In Tuesday's Mid-Day Session,2018-03-13 12:28:00-04:00,EPZM,neutral
430686.0,"Epizyme Reports Q4 EPS $(0.52) vs $(0.57) Est., No Sales",2018-03-13 07:42:00-04:00,EPZM,negative
430687.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-11 16:58:00-04:00,EPZM,neutral
430688.0,36 Biggest Movers From Yesterday,2018-01-11 04:37:00-05:00,EPZM,neutral
430689.0,"ICYMI: Epizyme, MoviePass, And A Bull Call On Novavax",2018-01-10 17:38:00-05:00,EPZM,neutral
430690.0,"Epizyme Shares Up 16.4%; Earlier Morgan Stanley Initiated Stock At Overweight, Saying Co. Has 'Blockbuster' Drug In The Making, Believes Share Price Doesn't Reflect Tazemetostat's Potential",2018-01-10 13:28:00-05:00,EPZM,positive
430691.0,34 Stocks Moving In Wednesday's Mid-Day Session,2018-01-10 12:32:00-05:00,EPZM,neutral
430692.0,Morgan Stanley: Epizyme Has 'Blockbuster' Cancer Drug In The Making,2018-01-10 10:26:00-05:00,EPZM,negative
430693.0,"Benzinga's Top Upgrades, Downgrades For January 10, 2018",2018-01-10 09:20:00-05:00,EPZM,positive
430694.0,"Morgan Stanley Initiates Coverage On Epizyme with Overweight Rating, Announces $20.00 Price Target",2018-01-10 07:34:00-05:00,EPZM,negative
430695.0,"Epizyme Introduces Next Drug Candidate, EZM266, The First of Three New Compounds to be Named as Part of Epizyme's Vision 2020",2017-12-11 07:32:00-05:00,EPZM,positive
430696.0,Epizyme Presents New Biomarker Data on Tazemetostat at #ASH2017,2017-12-10 11:52:00-05:00,EPZM,neutral
430697.0,66 Biggest Movers From Yesterday,2017-11-03 04:49:00-04:00,EPZM,neutral
430698.0,52 Stocks Moving In Thursday's Mid-Day Session,2017-11-02 12:29:00-04:00,EPZM,neutral
430699.0,"Benzinga's Top Upgrades, Downgrades For November 2, 2017",2017-11-02 09:13:00-04:00,EPZM,positive
430700.0,25 Stocks Moving In Thursday's Pre-Market Session,2017-11-02 08:25:00-04:00,EPZM,neutral
430701.0,RBC Capital Downgrades Epizyme to Sector Perform,2017-11-02 08:12:00-04:00,EPZM,neutral
430702.0,"Epizyme Q3 EPS $(0.63) vs $(0.65) Est., No Sales",2017-11-01 17:14:00-04:00,EPZM,negative
430703.0,"Epizyme Offers Data From Phase 1 Trial Of Tazemetostat In Children With Relapsed, Refractory INI-1Negative Solid Tumors: 'First presentation of pediatric dose escalation in tazemetostat, showing favorable safety, tolerability'",2017-10-27 09:19:00-04:00,EPZM,positive
430704.0,"Epizyme Shares Make New 52-Week High Of $20.44, Now Up 6.3% At $20.25",2017-10-02 11:31:00-04:00,EPZM,positive
430705.0,"Benzinga's Top Upgrades, Downgrades For September 20, 2017",2017-09-20 09:12:00-04:00,EPZM,positive
430706.0,"Jefferies Initiates Coverage On Epizyme with Buy Rating, Announces $23.00 Price Target",2017-09-20 06:17:00-04:00,EPZM,neutral
430707.0,12 Biggest Mid-Day Losers For Thursday,2017-09-14 13:01:00-04:00,EPZM,negative
430708.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-09-14 08:06:00-04:00,EPZM,neutral
430709.0,Epizyme Prices 9.18M Share Offering at $15.25/Share,2017-09-14 06:32:00-04:00,EPZM,positive
430710.0,"5 Stocks To Watch For September 14, 2017",2017-09-14 04:32:00-04:00,EPZM,neutral
430711.0,Epizyme Announces $120M Share Offering Common Stock,2017-09-13 16:01:00-04:00,EPZM,positive
430712.0,Epizyme CFO to Step Down to Pursue Other Opportunities,2017-08-15 06:34:00-04:00,EPZM,positive
430713.0,20 Biggest Mid-Day Gainers For Friday,2017-08-04 12:41:00-04:00,EPZM,neutral
430714.0,28 Stocks Moving In Friday's Pre-Market Session,2017-08-04 08:30:00-04:00,EPZM,neutral
430715.0,"Epizyme Reports Q2 EPS $(0.48) vs $(0.55) Est., Sales $10M vs $2.83M Est.",2017-08-04 06:38:00-04:00,EPZM,neutral
430716.0,Epizyme Reports Tazemetostat to be Evaluated in NCI's Recently Initiated NCI-COG Pediatric MATCH Trial,2017-07-24 16:09:00-04:00,EPZM,neutral
430717.0,"Epizyme Chief Scientific Officer Robert Copeland to Retire Effective June 30, 2017 -8-K",2017-06-28 06:13:00-04:00,EPZM,positive
430719.0,Epizyme To Collaborate with Genetech for Collaboration on TECENTRIQ,2017-06-26 06:32:00-04:00,EPZM,neutral
430720.0,15 Biggest Mid-Day Gainers For Wednesday,2017-06-21 12:23:00-04:00,EPZM,neutral
430721.0,Epizyme's Tazemetostat Granted Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma,2017-06-21 06:30:00-04:00,EPZM,positive
430723.0,Epizyme Receives FDA Orphan Designation for Tazemetostat,2017-06-18 21:45:00-04:00,EPZM,neutral
430726.0,10 Biggest Mid-Day Losers For Wednesday,2017-06-14 13:09:00-04:00,EPZM,negative
430727.0,Epizyme Shares Quiet Here As Traders Circulating Positive Comments From Leerink,2017-06-14 10:20:00-04:00,EPZM,positive
430728.0,UPDATE: Epizyme Says Interim Data For Tazemetostat Showed Treatment Resulted In Clinically Meaningful Benefit In Patients With FL,2017-06-14 08:34:00-04:00,EPZM,positive
430729.0,"Epizyme Reports Interim Data From Phase 2 Trial For Tazemetostat In Relapsed, Refractory Follicular Lymphoma, DLBCL Patients",2017-06-14 08:33:00-04:00,EPZM,neutral
430731.0,"Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data",2017-06-05 13:48:00-04:00,EPZM,neutral
430732.0,Epizyme Announces Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Data to be Presented at ASCO,2017-05-18 06:07:00-04:00,EPZM,positive
430733.0,"Epizyme Q1 EPS $(0.56) vs $(0.63) Est, No Sales",2017-05-08 07:24:00-04:00,EPZM,negative
430734.0,Epizyme Reports Earned $10M Milestone Payment from GlaxoSmithKline Related to Initiation of GLP Toxicology Studies with Novel Methyltransferase Inhibitor,2017-05-04 06:48:00-04:00,EPZM,positive
430735.0,20 Biggest Mid-Day Gainers For Tuesday,2017-04-25 12:43:00-04:00,EPZM,neutral
430736.0,Epizyme Granted Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML,2017-04-25 06:40:00-04:00,EPZM,positive
430737.0,"Oppenheimer Initiates Coverage On Epizyme with Outperform Rating, Announces $26.00 Price Target",2017-04-13 09:11:00-04:00,EPZM,neutral
430738.0,"Epizyme Says Pres of Research, Chief Scientific Officer, Robert Copeland, to Retire",2017-03-09 06:44:00-05:00,EPZM,neutral
430739.0,"Epizyme Expects Cash, Cash Equivalents, Marketable Securities of $242.2M to be Sufficient to Fund Co.'s Planned Operations Through At Least Q3'18",2017-03-09 06:43:00-05:00,EPZM,positive
430740.0,"Epizyme Reports Q4 Loss $35M vs $22M Loss in Same Qtr. Last Year, Collaboration Sales $500K vs $600K YoY",2017-03-09 06:42:00-05:00,EPZM,negative
430741.0,Epizyme Receives Written Positive Response From FDA Allowing Enrollment Of Patients With Follicular Lymphoma,2017-01-19 08:54:00-05:00,EPZM,positive
430742.0,Good And Bad News from Epizyme; Wedbush Analyst Weighs In,2016-11-28 15:26:00-05:00,EPZM,negative
430743.0,A Peek Into The Markets: U.S. Stock Futures Signal Lower Start On Wall Street,2016-11-28 07:39:00-05:00,EPZM,negative
430744.0,Epizyme Gets Fast Track Designation for Tazemetostat,2016-11-28 06:32:00-05:00,EPZM,neutral
430745.0,"Epizyme Q3 EPS $(0.42) vs $(0.60) Est, Revenue $6.6K vs $470K",2016-11-03 06:45:00-04:00,EPZM,neutral
430746.0,Epizyme to Expand Clinical Programs with National Cancer Insitute,2016-10-31 06:42:00-04:00,EPZM,negative
430747.0,Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer Institute,2016-10-31 06:34:00-04:00,EPZM,negative
430748.0,Epizyme Gets $6M Milestone Payment from GlaxoSmithKline,2016-09-15 06:30:00-04:00,EPZM,neutral
430749.0,Epizyme Reports Dosing of First Patient in Phase 2 Study Evaluating Tazemetostat in Mesothelioma,2016-08-11 06:33:00-04:00,EPZM,neutral
430750.0,Mid-Afternoon Market Update: Crude Oil Up 3.5%; Ceragon Shares Drop Following Q2 Results,2016-08-08 14:31:00-04:00,EPZM,negative
430751.0,12 Biggest Mid-Day Losers For Monday,2016-08-08 13:07:00-04:00,EPZM,negative
430752.0,Mid-Day Market Update: Mattress Firm Jumps Following Buyout; Digital Ally Shares Slide,2016-08-08 12:05:00-04:00,EPZM,positive
430753.0,"Epizyme Q2 EPS ($0.49) vs ($0.52) est, Revenue $473K vs $880K est",2016-08-08 06:32:00-04:00,EPZM,neutral
430754.0,Epizyme Initiates Collaboration on Combination Trial of Tazemetostat and Tecentriq for Treatment of Non-Hodgkin Lymphoma,2016-06-22 12:10:00-04:00,EPZM,neutral
430755.0,6 Biggest Mid-Day Losers For Monday,2016-06-20 13:00:00-04:00,EPZM,negative
430756.0,Mid-Day Market Update: Crude Oil Rises 2.5%; Epizyme Shares Drop,2016-06-20 12:11:00-04:00,EPZM,negative
430757.0,Mid-Morning Market Update: Markets Open Higher; Icahn Enterprises Raises Offer For Federal Mogul,2016-06-20 10:01:00-04:00,EPZM,neutral
430758.0,Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting,2016-06-19 21:42:00-04:00,EPZM,neutral
430759.0,"Epizyme Q1 EPS ($0.41) vs ($0.53) est, Revenue $472K vs $900K est",2016-05-09 06:41:00-04:00,EPZM,neutral
430760.0,Epizyme Announces Collaboration with Lymphoma Study Association to Evaluate Combination of Tazemetostat with R-CHOP,2016-05-09 06:39:00-04:00,EPZM,neutral
430761.0,Epizyme Names Matthew Ros COO,2016-05-06 08:11:00-04:00,EPZM,neutral
430762.0,Epizyme Says FDA Accepts INDA for Its Tazemetostat In Mesothelioma,2016-05-04 07:53:00-04:00,EPZM,positive
430763.0,Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Mesothelioma,2016-05-04 06:35:00-04:00,EPZM,positive
430764.0,Epizyme Names Susan Graf Chief Business Officer,2016-04-25 08:01:00-04:00,EPZM,neutral
430765.0,"Epizyme Shows Data From 13-Patient Study Showing Tazemetostat Can Be Administered With or Without Food, Only A Weak Inducer Of CYP3A-Mediated Metabolism",2016-04-18 09:03:00-04:00,EPZM,positive
430766.0,"Citigroup Initiates Coverage on Epizyme at Buy, Announces $17.00 PT",2016-04-05 06:04:00-04:00,EPZM,neutral
430767.0,Why These 5 Stocks Are Moving After Hours,2016-03-23 16:55:00-04:00,EPZM,neutral
430768.0,Benzinga's Top Upgrades,2016-03-14 09:07:00-04:00,EPZM,positive
430769.0,"H.C. Wainwright Upgrades Epizyme to Buy, Raises PT to $25.00",2016-03-14 07:16:00-04:00,EPZM,neutral
430770.0,Epizyme Q4 Earnings Conference Call: Full Transcript,2016-03-09 14:10:00-05:00,EPZM,neutral
430771.0,"Epizyme Q4 EPS ($0.53) vs ($0.65) est, Revenue $555K vs $570K est",2016-03-09 06:34:00-05:00,EPZM,neutral
430772.0,Epizyme Says Focused on Accelerating Development of Tazemetostat,2016-03-09 06:32:00-05:00,EPZM,positive
430773.0,Epizyme Gives Pipeline Objectives Through 2020,2016-03-09 06:31:00-05:00,EPZM,neutral
430774.0,"Earnings Scheduled For March 9, 2016",2016-03-09 04:07:00-05:00,EPZM,neutral
430775.0,Patrick Lee Reports 6.38% Passive Stake in Epizyme in 13G,2016-02-16 14:37:00-05:00,EPZM,positive
430776.0,Epizyme Reports FDA Grants ODD For Tazemetostat For Treatment Of Malignant Rhabdoid Tumors,2016-02-08 08:03:00-05:00,EPZM,negative
430777.0,Here's Why There's Been A Rush Of Biotech Offerings,2016-01-07 11:32:00-05:00,EPZM,neutral
430778.0,Mid-Morning Market Update: Markets Open Lower; KB Home Misses Q4 Views,2016-01-07 09:54:00-05:00,EPZM,negative
430779.0,Benzinga's Top #PreMarket Losers,2016-01-07 08:28:00-05:00,EPZM,negative
430780.0,Epizyme Prices ~13.33M Share Offering @$9.00/Share,2016-01-07 04:06:00-05:00,EPZM,positive
430781.0,Mid-Afternoon Market Update: Dow Slides Over 300 Points; Otonomy Shares Tumble Following Public Offering Of Stock,2016-01-06 14:57:00-05:00,EPZM,positive
430782.0,Mid-Day Market Update: Crude Oil Falls Over 4%; Conatus Pharmaceuticals Shares Rise Following Positive Results In Phase 2 Study,2016-01-06 12:14:00-05:00,EPZM,positive
430783.0,Mid-Morning Market Update: Markets Open Lower; Monsanto Posts Narrower-Than-Expected Loss,2016-01-06 10:07:00-05:00,EPZM,negative
430784.0,Notable Buy-Side Biotech Analyst Brad Loncar Notes Heavy Biotech Offerings Taking Place After Hours In Tweet,2016-01-05 16:15:00-05:00,EPZM,neutral
430785.0,Epizyme Reports Offering of $120M Shares,2016-01-05 16:01:00-05:00,EPZM,positive
430786.0,"Epizyme Reports First Patient Dosed in Clinical Program Evaluating Tazemetostat; Says Now Enrolling Adults in Phase 2 Study, Pediatric Patients in Escalation Study",2015-12-30 08:05:00-05:00,EPZM,neutral
430787.0,10 Biotechs Short Sellers Are Betting Against,2015-12-29 08:22:00-05:00,EPZM,neutral
430788.0,"JMP Securities Sees Epizyme's Tazemetostat Acceptance Easing Investor Concern, Views Step As Noteworthy For Company Going Forward",2015-12-29 07:24:00-05:00,EPZM,positive
430789.0,Epizyme Reports FDA Acceptance of INDA for Tazemetostate in Diffuse Large B-Cell Lymphoma,2015-12-28 08:00:00-05:00,EPZM,positive
430790.0,"SunTrust Robinson Humphrey Initiates Coverage on Epizyme at Buy, Announces $21.00 PT",2015-12-22 16:58:00-05:00,EPZM,neutral
430791.0,"Epizyme Reports Updated Data from Ongoing Phase 1 Study of Tazemetostat Showing Objective, Durable Responses in Relapsed, Refractory NHL",2015-12-07 08:02:00-05:00,EPZM,neutral
430792.0,"Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now",2015-10-06 14:08:00-04:00,EPZM,neutral
430793.0,Epizyme Updated Tazemetostat Phase 1 Data Show Clinical Activity in a Broader Range of Adults With INI1-Negative and SMARCA4-Negative Solid Tumors,2015-09-26 06:46:00-04:00,EPZM,positive
430794.0,Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma,2015-08-24 08:02:00-04:00,EPZM,positive
430795.0,10 Biotech Stocks With Catalysts Coming Soon,2015-08-20 12:19:00-04:00,EPZM,neutral
430796.0,Benzinga's Top Downgrades,2015-07-20 09:27:00-04:00,EPZM,positive
430797.0,"H.C. Wainwright Destroys Epizyme Price Target, Sees 'No Material Value Drivers'",2015-07-20 08:33:00-04:00,EPZM,negative
430798.0,"H.C. Wainwright Downgrades Epizyme to Neutral, Lowers PT to $22.00",2015-07-20 07:19:00-04:00,EPZM,negative
430799.0,Epizyme Doses First Patient in Five-Arm Phase 2 Study for First-in-Class EZH2 Inhibitor Tazemetostat (EPZ-6438) in Relapsed or Refractory Non-Hodgkin Lymphoma,2015-07-09 16:00:00-04:00,EPZM,negative
430800.0,"Epizyme Reports Extension of Celgene Research Collab, Will Receive $10M Fee Payment, Up to $610M in Potential Milestones",2015-07-09 07:03:00-04:00,EPZM,neutral
430801.0,Benzinga's Top Initiations,2015-07-06 09:57:00-04:00,EPZM,positive
430802.0,RBC Capital Initiates Epizyme With Outperform,2015-07-06 09:33:00-04:00,EPZM,neutral
430803.0,"RBC Capital Initiates Coverage on Epizyme at Outperform, Announces $40.00 PT",2015-07-06 06:46:00-04:00,EPZM,neutral
430804.0,Epizyme to Show Clinical Data from Ongoing Phase 1 Dose Escalation Trial of Tazemetostat at the European Cancer Congress,2015-06-29 16:34:00-04:00,EPZM,negative
430805.0,"Tuesday's Mid-Day Movers: Ambarella Retaliates; Sonic, BlackBerry Hit",2015-06-23 11:51:00-04:00,EPZM,neutral
430806.0,Watch These 10 After-Hours Movers Today,2015-06-23 06:59:00-04:00,EPZM,neutral
430807.0,Mid-Afternoon Market Update: Williams Surges Following Bid from ETE; Ambarella Shares Slide,2015-06-22 15:06:00-04:00,EPZM,positive
430808.0,"Monday's Mid-Day Movers: Williams Companies, GoPro, Ambarella And More",2015-06-22 14:11:00-04:00,EPZM,neutral
430809.0,Mid-Day Market Update: Martha Stewart Living Omnimedia Drops After Sequential Buyout Deal; CIGNA Shares Gain,2015-06-22 13:52:00-04:00,EPZM,positive
430810.0,Benzinga's Volume Movers,2015-06-22 12:29:00-04:00,EPZM,neutral
430811.0,Mid-Morning Market Update: Markets Open Higher; Williams Companies Rejects Energy Transfer Equity Buyout Offer,2015-06-22 10:53:00-04:00,EPZM,negative
430812.0,Morning Market Gainers,2015-06-22 09:43:00-04:00,EPZM,neutral
430813.0,Epizyme Reports Positive Data from Ongoing Phase 1 Study of Tazemetostat in Relapsed or Refractory NHL,2015-06-20 13:52:00-04:00,EPZM,positive
430814.0,Epizyme Reports Q1 EPS -$1.75 Vs Est -$0.99 May Not Compare,2015-04-28 16:57:00-04:00,EPZM,neutral
430815.0,Epizyme Reports Preclinical Research Providing Deeper Understanding of Multiple Cancer Targets,2015-04-20 17:36:00-04:00,EPZM,negative
430816.0,Epizyme Will Present Updated Data from Ongoing Phase 1 Dose Escalation Trial of EZH2 Inhibitor EPZ-6438 at International Conference on Malignant Lymphoma,2015-04-20 08:31:00-04:00,EPZM,negative
430817.0,"Regulus Therapeutics, Healthcare Stocks Are Big Movers In Tuesday's After Hours Trading",2015-04-07 20:39:00-04:00,EPZM,neutral
430818.0,Epizyme Prices 6M Share Offering @$20.75/Share,2015-03-18 04:45:00-04:00,EPZM,positive
430819.0,"Epizyme Announces Proposed Public Offering of Common Stock, 4.75M",2015-03-16 16:11:00-04:00,EPZM,neutral
430820.0,Morning Market Losers,2015-03-12 09:56:00-04:00,EPZM,negative
430821.0,Epizyme Q4 EPS -$0.44 vs -$0.53 est,2015-03-12 07:07:00-04:00,EPZM,neutral
430822.0,Epizyme Announces Presentation of Data from Phase 1 Study of EZH2 Inhibitor EPZ-6438 (E7438),2015-03-03 08:05:00-05:00,EPZM,negative
430823.0,Epizyme Appoints Andrew Singer as Chief Financial Officer,2015-02-03 08:06:00-05:00,EPZM,neutral
430824.0,"Primecap Exceeds 5% Threshold In Shutterfly, 3 Other Companies",2015-01-06 15:51:00-05:00,EPZM,neutral
430825.0,From Amended 13G: Primecap Reports Increased Stake In Epizyme Now 12.04%,2015-01-06 11:21:00-05:00,EPZM,positive
430826.0,"Epizyme Announces DOT1L Inhibitor EPZ-5676 Shows Clinical, Biological Activity in Adult Patients with Acute Leukemias; Separately Reports PRMT5 Inhibitor Showed In Vitro, In Vivo Activity",2014-12-08 13:32:00-05:00,EPZM,negative
430827.0,"Mid-Day Gainers From November 20: Kirkland's, Americas Car-Mart, Cyberonics, Epizyme, Dillard's, Best Buy",2014-11-20 12:08:00-05:00,EPZM,positive
430828.0,"Midday Losers From November 6: Qualcomm, Genworth Financial, Epizyme, Nationstar Mortgage",2014-11-06 13:29:00-05:00,EPZM,negative
430829.0,Morning Market Losers ,2014-11-06 09:56:00-05:00,EPZM,negative
430830.0,Epizyme Reports Q3 EPS of $(0.58) vs $(0.55) Est; Revenue of $8.18M vs $6.93M Est,2014-11-06 07:34:00-05:00,EPZM,neutral
430831.0,Epizyme Announces Departure of Chief Medical Officer Eric Hedrick ,2014-10-27 08:04:00-04:00,EPZM,neutral
430832.0,Epizyme Announces Notices of Allowance for US Patent Applications Covering PRMT5 Inhibitors and Methods of Cancer Treatment with PRMT5 Inhibitors ,2014-10-23 08:33:00-04:00,EPZM,negative
430833.0,Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) ,2014-10-17 08:03:00-04:00,EPZM,negative
430834.0,Epizyme Announces Clinical And Pre-Clinical Data To Be Featured In Oral And Poster Presentations At American Society Of Hematology (ASH) Annual Meeting,2014-10-10 08:01:00-04:00,EPZM,neutral
430835.0,UPDATE: Mizuho Securities USA Initiates Coverage On Epizyme Inc On Epigenetics Pure Play,2014-09-12 09:39:00-04:00,EPZM,positive
430836.0,Benzinga's Top Initiations,2014-09-12 08:13:00-04:00,EPZM,positive
430837.0,Mizuho Securities Initiates Epizyme With Buy,2014-09-12 08:11:00-04:00,EPZM,positive
430838.0,"CORRECTION: Mizuho Securities Initiates Coverage on Epizyme at Buy, Announces $35.00 PT",2014-09-12 05:47:00-04:00,EPZM,positive
430839.0,"Mizuho Securities Initiates Coverage on Epizyme at Buy, Announces $35.00 PT",2014-09-12 05:46:00-04:00,EPZM,positive
430840.0,Epizyme Announces Resignation Of President & CFO Jason Rhodes ,2014-09-02 16:32:00-04:00,EPZM,negative
430841.0,"Epizyme, Inc. Announces Resignation Of President And CFO Jason Rhodes",2014-09-02 16:31:00-04:00,EPZM,negative
430842.0,Epizyme Reports Q2 EPS of $(0.40) vs $(0.50) Est,2014-08-13 07:32:00-04:00,EPZM,neutral
430843.0,"Epizyme Offers Pre-Clinical Data, Early Clinical Observations from EPZ-6438 Trial, Maximum Tolerated Dose Not Reached, Evidence of Target Inhibition Observed",2014-08-12 17:03:00-04:00,EPZM,negative
430844.0,"UPDATE: H.C. Wainwright & Co. Initiates Coverage On Epizyme, Transition Therapeutics",2014-07-15 11:22:00-04:00,EPZM,neutral
430845.0,Epizyme Shares Quiet Following S-3 Filing Showing Registration for $200M Mixed Securities Shelf,2014-06-12 11:04:00-04:00,EPZM,positive
430846.0,Epizyme Reports Q1 EPS of $(0.22) vs $(0.47) Est; Revenue of $13.40M vs $8.48M Est,2014-05-13 16:01:00-04:00,EPZM,neutral
430847.0,"Epizyme Reports Has Achieved Lead Candidate Milestone for Third Target in GSK Collab, Receives $4M in Milestone, License Payments",2014-04-22 08:12:00-04:00,EPZM,neutral
430848.0,"Epizyme Wins Patent Covering Diagnosis, Treatment of Cancers with EZH2 Mutation",2014-04-08 07:33:00-04:00,EPZM,positive
430849.0,Epizyme Reports Q4 EPS of $0.52 vs $(0.22) Est; Revenue of $15.90M vs $15.63M Est,2014-02-27 16:08:00-05:00,EPZM,neutral
430850.0,Epizyme Announces Publication Shows Positive Preclinical Data for EPZ-6438 in Genetically Non-Hodgkin Lymphoma ,2014-02-21 08:18:00-05:00,EPZM,positive
430851.0,Epizyme Announces Pricing of Public Offering of Common Stock at $29.25 per Share,2014-02-05 08:03:00-05:00,EPZM,positive
430852.0,Epizyme Offers 4.192M Shares of Common Stock at Proposed Maximum Offering Price of $144.5M,2014-02-03 06:50:00-05:00,EPZM,positive
430853.0,Market Wrap For January 7: Markets Reverse 3-Day Slump,2014-01-07 16:39:00-05:00,EPZM,neutral
430854.0,Mid-Morning Market Update: Markets Open Higher; IHS Profit Beats Estimates,2014-01-07 11:38:00-05:00,EPZM,positive
430855.0,Benzinga's Volume Movers,2014-01-07 11:03:00-05:00,EPZM,neutral
430856.0,Morning Market Movers ,2014-01-07 10:07:00-05:00,EPZM,neutral
430857.0,Benzinga Weekly Preview: PMI Data In Focus,2013-11-15 16:59:00-05:00,EPZM,neutral
430858.0,UPDATE: Citigroup Reiterates on Epizyme Awaiting Further Clarity,2013-11-15 08:12:00-05:00,EPZM,positive
430859.0,"Citigroup Maintains Buy on Epizyme, Lowers PT to $32.00",2013-11-15 07:43:00-05:00,EPZM,negative
430860.0,Epizyme Reports Q3 EPS of $(0.34) vs $(0.30) Est; Revenue of $8.44M vs $9.50M Est,2013-10-22 16:21:00-04:00,EPZM,neutral
430861.0,"UPDATE: Epizyme Leukemia Drug Receives FDA Orphan Drug Designation, Not Yet Approved",2013-08-12 13:21:00-04:00,EPZM,negative
430862.0,Epizyme Leukemia Treatment Gets Orphan Drug Status From FDA - Bloomberg,2013-08-12 13:10:00-04:00,EPZM,neutral
430863.0,Epizyme Reports Q2 EPS of $(0.25) Which May Not Compare $(0.36) Est; Revenue of $14.80M Which May Not Compare $13.40M Est,2013-07-31 16:01:00-04:00,EPZM,neutral
430864.0,"Market Wrap for Tuesday, July 9: Major Averages Closing in on Previous Highs ",2013-07-09 16:28:00-04:00,EPZM,neutral
430865.0,"Epizyme, Inc. Appoints Jason P. Rhodes President",2013-07-03 08:31:00-04:00,EPZM,neutral
430866.0,"Epizyme, Inc. Added to Russell 2000 Index",2013-07-01 08:32:00-04:00,EPZM,neutral
430867.0,UPDATE: Wedbush Initiates Epizyme at Outperform on Therapeutics Targeting HMTs,2013-06-27 08:19:00-04:00,EPZM,neutral
430868.0,"Wedbush Initiates Coverage on Epizyme at Outperform, Announces $37.00 PT",2013-06-27 06:26:00-04:00,EPZM,neutral
430869.0,"Epizyme, Inc. Publishes Data Demonstrating EPZ-5676 as Potent, Selective Inhibitor of DOT1L for Genetically Defined Acute Leukemias ",2013-06-26 08:31:00-04:00,EPZM,negative
430870.0,"JMP Securities Initiates Coverage on Epizyme at Outperform, Announces $40.00 PT",2013-06-25 09:11:00-04:00,EPZM,positive
430871.0,Leerink Swann Initiates Coverage on Epizyme at Outperform,2013-06-25 09:11:00-04:00,EPZM,neutral
430872.0,Benzinga's Top Initiations,2013-06-25 08:03:00-04:00,EPZM,positive
430873.0,"Citigroup Initiates Coverage on Epizyme at Buy, Announces $32.00 PT",2013-06-25 06:28:00-04:00,EPZM,neutral
430874.0,EXCLUSIVE: OTC Markets CEO Answers the Question: 'Is it Wise to Go Public?',2013-06-12 12:18:00-04:00,EPZM,positive
430875.0,Afternoon Market Losers,2013-06-05 15:40:00-04:00,EPZM,negative
430876.0,Shares of Epizyme Open for Trade at $20 After Pricing at $15/Share,2013-05-31 10:31:00-04:00,EPZM,positive
430877.0,"Epizyme Shares to Open for Trade at 10:20AM EDT, Priced 5.14M Shares at $15/Share",2013-05-31 10:06:00-04:00,EPZM,positive
430878.0,Epizyme Files IPO for 4.285M Shares,2013-05-13 14:11:00-04:00,EPZM,positive
